Compass Capital Corp MA ADV Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Compass Capital Corp MA ADV increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,072 shares of the biopharmaceutical company’s stock after purchasing an additional 615 shares during the period. Compass Capital Corp MA ADV’s holdings in Pfizer were worth $1,253,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the 4th quarter worth $27,000. Gould Capital LLC lifted its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on PFE shares. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $23.88 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market capitalization of $135.74 billion, a P/E ratio of 17.30, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company’s fifty day moving average is $23.17 and its two-hundred day moving average is $24.92.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the company posted $0.82 earnings per share. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.20%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.